UNIVERSAL IBOGAINE INCUU

UNIVERSAL IBOGAINE INC

0.030CADD
+0.005+20.00%
Last update at May 27, 17:10 GMT
CAD
No tradesPre-market
See on Supercharts

IBO fundamentals

Key facts

Market capitalization‪8.24 M‬CAD
Basic EPS (TTM)−0.01CAD
Founded2018
CEONicholas Peter Karos
About

Universal Ibogaine, Inc. engages in developing ibogaine based drug franchise to treat addiction and related mental health issues. The company was founded by Shayne Nyquvest and Alberto Solá Agulló in 2018 and is headquartered in Calgary, Canada.

Ownership
‪‪274.83 M‬‬
Free Float shares
‪‪247.83 M‬‬ (90.18%)
Closely held shares
‪‪27.00 M‬‬ (9.82%)
Free Float shares
‪‪247.83 M‬‬ (90.18%)
Closely held shares
‪‪27.00 M‬‬ (9.82%)
Capital structure
Market cap
‪‪8.24 M‬‬
Debt
‪‪2.60 M‬‬
Cash & equivalents
‪‪274.06 K‬‬
Enterprise value
‪‪10.57 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪8.24 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.07x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.07x
Valuation ratios
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
‪3.60‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−175%‬
‪−140%‬
‪−105%‬
‪−70%‬
‪−35%‬
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−1.00 M‬‬
‪‪−500.00 K‬‬
‪0.00‬
‪‪500.00 K‬‬
‪‪1.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−400.00 K‬‬
‪‪−200.00 K‬‬
‪0.00‬
‪‪200.00 K‬‬
‪‪400.00 K‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−400.00 K‬‬
‪‪−200.00 K‬‬
‪0.00‬
‪‪200.00 K‬‬
‪‪400.00 K‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Addiction Treatment Clinics and Ibogaine
By country
Period: 2024
Canada

Dividends

Dividend yield, history and sustainability

No dividends
IBO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪‪−1.00 M‬‬
‪0.00‬
‪‪1.00 M‬‬
‪‪2.00 M‬‬
‪‪3.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪900.00 K‬‬
‪‪1.80 M‬‬
‪‪2.70 M‬‬
‪‪3.60 M‬‬
Assets
Liabilities